The turnaround in CSL Ltd (ASX: CSL) shares has been sharp.
From the nine-year low struck on 3 June 2026, CSL has surged approximately 35% to $122.89.
The question is not whether the bounce has happened. It clearly has.
The question is what is driving it, whether those drivers are durable, and what the August FY26 result will need to show to confirm this is more than a sentiment swing.
Image source: Getty Images
What has driven the 35% rebound in CSL shares
The honest answer is that the recovery has been driven primarily by sector rotation and valuation recognition rather than new positive company-specific news.
Healthcare was the worst-performing sector of all eleven ASX 200 market sectors in FY26. The S&P/ASX 200 Health Care Index (ASX: XHJ) fell 39% over twelve months to hit a nine-year low on 3 June.
When a sector falls that far that fast, it tends to attract bargain-hunting institutional investors at the start of a new financial year. This is even more true when those same investors have just locked in large profits in resources and energy shares.
The underlying business has not changed materially in the six weeks since 3 June.
Management's FY26 guidance of approximately US$15.2 billion in revenue and US$3.1 billion in NPATA on a constant currency basis remains unchanged.
The operational challenges, including US immunoglobulin supply constraints and China albumin pricing pressure, remain the same.
The case that the recovery is here to stay
At the 3 June low of approximately $91, CSL was trading at approximately 11 times forecast FY26 earnings. This was a valuation not seen in more than fifteen years for a business of this quality.
At $122.89, CSL trades at approximately 15.2 times forecast FY26 earnings, still a fraction of the 30 to 50 times multiple it commanded at its peak.
Morgans retains a buy rating with a price target of $147.59, implying upside of approximately 20% from the current price.
To support this thesis, management has also pointed to stronger Behring division revenue growth in the second half of FY26. Additionally, management expects moderately stronger-than-expected Seqirus vaccine performance.
These are all early signs that the operating recovery is beginning.
The case that it is just a temporary bounce
The more cautious reading is equally legitimate.
Eight of eighteen analysts covering CSL have a buy rating, while ten have a hold.
That split reflects the uncertainty around today's share price.
Indeed, CSL has delivered a series of earnings disappointments over the past eighteen months. Each has been framed by management as temporary before proving more persistent than expected.
The FY26 result, due on 19 August, will be the most important test of whether the recovery has earnings support or is simply a valuation-driven sentiment swing.
If August delivers another round of guidance cuts, the 35% bounce could reverse quickly.
What the August result needs to show for CSL shares
Three things would confirm the recovery is real.
First, Behring division revenue growth in the second half of FY26 that confirms rather than falls short of management's guidance.
Second, evidence that the immunoglobulin supply and pricing situation is moving in the right direction.
Third, confidence from the new CEO, expected to be named before the result, that the operational challenges have a visible resolution path.
If those three conditions are met on 19 August, CSL's recovery from $91 to $122.89 will look like the early innings of something more sustained.
If they are not, investors who bought the bounce may face a difficult reassessment.
Foolish takeaway
CSL shares are up 35% since early June to $122.89, but remain down 49% over twelve months.
The recovery may be here to stay, reflecting an oversold valuation at the June lows.
It may also partly be a rotation bounce, driven by institutional new-year rebalancing rather than company-specific positive news.
The August FY26 result will separate those two explanations cleanly.
Until then, the honest answer to whether the recovery is real is: we do not yet know.
